TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
用于评估治疗反应的结核病替代标志物(结核病 SMART 研究)
基本信息
- 批准号:8793680
- 负责人:
- 金额:$ 115.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-02-12 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsBindingBioinformaticsBiological AssayBiological MarkersBloodCatalogingCatalogsCellsCenters for Disease Control and Prevention (U.S.)ChildClassificationClinicalClinical DataClinical TrialsCoughingCulture MediaDataData SetDatabasesDetectionDevelopmentDiagnosticDiseaseDoseDrug KineticsDrug resistanceDrug resistance in tuberculosisDrug toxicityEnrollmentExtreme drug resistant tuberculosisFailureFundingGoalsGoldGrowthHIVHumanImmunoassayIntentionLeadLinkLiquid substanceMeasurementMeasuresMembraneMonitorMoxifloxacinMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseNew AgentsOutcomeParticipantPatient NoncompliancePatientsPerformancePharmaceutical PreparationsPharmacodynamicsPhasePhase II Clinical TrialsPhase II/III TrialProbabilityProteomicsPulmonary TuberculosisQualifyingRandomizedRandomized Clinical TrialsReagentRecording of previous eventsRecoveryRegimenRelapseSample SizeSamplingScientistSerumSignal TransductionSpecimenSpeedSputumSurrogate MarkersTestingTimeTreatment FailureTreatment ProtocolsTuberculosisValidationVesiclearmbactericidebasecostdesigndrug developmentdrug efficacyefficacy testingfollow-upimprovedindustry partnerliquid chromatography mass spectrometrymacromoleculenext generationnovelpathogenprogramsprospectiveprototypepublic health relevancerepositoryresistant strainresponserifapentinesuccesstooltreatment responsetreatment trialtuberculosis drugstuberculosis treatmentvalidation studies
项目摘要
DESCRIPTION (provided by applicant): The current recommended 6-month treatment regimen for active tuberculosis (TB) is more than 40 years old and suffers from issues with drug toxicity and high rates of patient non-adherence, which combined have contributed to the emergence of drug resistant strains. For the first time in decades, the TB drug development pipeline is filled with several promising new agents that will soon be ready for phase 2 and phase 3 trials. However, testing the efficacy of these agents in clinical trials is a significant challenge because the conventional sputum-based, growth-based, microbiologic trial endpoints have notable technical and logistical weaknesses. For this proposal, entitled TB Surrogate Markers for Assessing Response to Treatment (TB SMART Study), our objective is to develop a blood-based, quantitative, host and pathogen-specific biomarker assay using a proven, high sensitivity, multiplexed electrochemiluminescence (ECL) platform that can, in combination with clinical data, supplant 2-month sputum culture, the current dichotomous Phase 2 trial endpoint. A non-sputum, non-growth based biomarker assay applied early in the course of a trial that could replace microbiologic intermediate endpoints, while retaining or improving upon their ability to predict outcomes, could transform the pace and scope of TB drug development, and of global TB control. It may additionally have utility for monitoring treatment of paucibacillary disease as is often seen in children, extra-pulmonary TB, and HIV/TB. To achieve this goal, we have assembled an investigative team of academics with expertise in TB drug development; industry partners with expertise in both unbiased and directed approaches to biomarker discovery; exosome scientists; and statisticians with expertise in bioinformatic approaches to prediction and surrogate marker identification. We will take advantage of specimens linked to clinical, radiographic, microbiologic, and PK/PD data from well-characterized patients with culture-confirmed pulmonary TB enrolled in four studies: three CDC-funded, TB Trials Consortium randomized, clinical trials, and one FDA-funded repository linked to Phase 3 TB trials. We will use available clinical trial data and sample sets to: 1) Identify blood-based, host
and TB-specific biomarkers of treatment response using unbiased, targeted and exosome-enriched approaches 2) develop and qualify multi-parameter classifiers for predicting recognized microbiologic measures of bactericidal and sterilizing activity, using the host and pathogen biomarkers identified, and 3) develop, qualify and conduct validation studies of a finalist biomarker panel built on a multiplexed ECL platform. Upon completion of comprehensive qualification and validation studies proposed, we will be ready to release the multiplexed, ECL biomarker panel assay as "Qualified Kits" to be used and evaluated in prospective Phase 2 and 3 trials.
描述(由申请人提供):目前推荐的活动性结核病(TB)6个月治疗方案已有40多年的历史,并且存在药物毒性和患者不依从率高的问题,这些问题共同导致了耐药菌株的出现。几十年来,结核病药物开发管道首次充满了几种有前途的新药,这些新药将很快准备好进行2期和3期试验。然而,在临床试验中测试这些药物的疗效是一个重大挑战,因为传统的基于肿瘤、基于生长的微生物试验终点具有明显的技术和后勤弱点。对于这一名为TB Surrogate Markers for Assessing Response to Treatment(TB SMART Study)的提案,我们的目标是开发一种基于血液的、定量的、宿主和病原体特异性生物标志物检测,该检测使用经过验证的、高灵敏度的、多路复用的电化学发光(ECL)平台,结合临床数据,可以取代2个月的痰培养,这是目前的二分法II期试验终点。在试验过程早期应用一种非痰、非生长的生物标志物检测方法,可以取代微生物中间终点,同时保留或提高其预测结果的能力,可以改变结核病药物开发和全球结核病控制的步伐和范围。此外,它还可用于监测儿童常见的少杆菌病、肺外结核和HIV/TB的治疗。为了实现这一目标,我们组建了一个由具有结核病药物开发专业知识的学者组成的调查团队;在生物标志物发现的无偏见和定向方法方面具有专业知识的行业合作伙伴;外泌体科学家;以及在生物信息学方法预测和替代标志物鉴定方面具有专业知识的统计学家。我们将利用与临床、影像学、微生物学和PK/PD数据相关的标本,这些标本来自四项研究中入选的经培养确诊的肺结核患者,这些研究包括三项CDC资助的TB试验联盟随机临床试验和一项FDA资助的与III期TB试验相关的储存库。我们将使用现有的临床试验数据和样本集:1)确定血液,宿主
和TB特异性生物标志物的治疗反应2)开发和鉴定多参数分类器,用于使用鉴定的宿主和病原体生物标志物预测杀菌和消毒活性的公认微生物学测量,和3)开发、鉴定和进行基于多路ECL平台构建的最终生物标志物组的验证研究。在完成拟定的全面确认和验证研究后,我们将准备发布多重ECL生物标志物检测试剂盒,作为“合格试剂盒”,用于前瞻性II期和III期试验并进行评价。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAYAM NAHID其他文献
PAYAM NAHID的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAYAM NAHID', 18)}}的其他基金
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
用于评估治疗反应的结核病替代标志物(结核病 SMART 研究)
- 批准号:
8617797 - 财政年份:2013
- 资助金额:
$ 115.49万 - 项目类别:
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
用于评估治疗反应的结核病替代标志物(结核病 SMART 研究)
- 批准号:
8474583 - 财政年份:2013
- 资助金额:
$ 115.49万 - 项目类别:
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
用于评估治疗反应的结核病替代标志物(结核病 SMART 研究)
- 批准号:
9210047 - 财政年份:2013
- 资助金额:
$ 115.49万 - 项目类别:
TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
用于评估治疗反应的结核病替代标志物(结核病 SMART 研究)
- 批准号:
9005810 - 财政年份:2013
- 资助金额:
$ 115.49万 - 项目类别:
Interplay of strain and ethnicity in the immune response to M. tuberculosis
结核分枝杆菌免疫反应中菌株和种族的相互作用
- 批准号:
7195567 - 财政年份:2007
- 资助金额:
$ 115.49万 - 项目类别:
Interplay of strain and ethnicity in the immune response to M. tuberculosis
结核分枝杆菌免疫反应中菌株和种族的相互作用
- 批准号:
7500655 - 财政年份:2007
- 资助金额:
$ 115.49万 - 项目类别:
Interplay of strain and ethnicity in the immune response to M. tuberculosis
结核分枝杆菌免疫反应中菌株和种族的相互作用
- 批准号:
8131873 - 财政年份:2007
- 资助金额:
$ 115.49万 - 项目类别:
Interplay of strain and ethnicity in the immune response to M. tuberculosis
结核分枝杆菌免疫反应中菌株和种族的相互作用
- 批准号:
7679586 - 财政年份:2007
- 资助金额:
$ 115.49万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Continuing Grant
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Discovery Projects
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Fellowship
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Research Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Standard Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Discovery Projects
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 115.49万 - 项目类别:
Research Grant